Uncategorised

003 Use of Ospemifene is Associated with Improvements to the Vulva, Vestibule, and Vagina in Women with Genitourinary Syndrome of Menopause (GSM): A Prospective Vulvoscopic Analysis

 

Ospemifene is the first oral selective estrogen receptor modulator approved in the US for the treatment of mild to moderate dyspareunia due to menopause. Published data show improvement in pain scores and vaginal epithelial cell characteristics, however there are no published data with regard to vulvar changes. The aim of this prospective, open label clinical trial was to study, in menopausal women taking 60 mg daily ospemifene, changes to the vulva, vestibule and vaginal region over 20 weeks using vulvoscopy.

003 Use of Ospemifene is Associated with Improvements to the Vulva, Vestibule, and Vagina in Women with Genitourinary Syndrome of Menopause (GSM): A Prospective Vulvoscopic Analysis

2018-06

The Journal of Sexual Medicine

https://www.jsm.jsexmed.org/article/S1743-6095(18)30193-0/fulltext?rss=yes

Leave a Reply